

Supplementary Table S1. Baseline characteristics of the study participants (n = 10,325)^a

Supplementary Table S2. Contribution of the seven flavonoid subclasses to flavonoid intake (n = 10,325)

Supplementary Table S3. Incidence rate ratio of hypertension by quartiles of dietary intake of flavonoids and their subclasses (n = 10,325)

Supplementary Table S4. Incidence rate ratio of hypertension by quartiles of dietary intake of 35 individual flavonoid compounds (n = 10,325)

Supplementary Figure S1. Timeline of study follow-up in KoGES_CAVAS cohort

Supplementary Figure S2. Flowchart of study in KoGES_CAVAS cohort

Supplementary Table S1. Baseline characteristics of the study participants (n = 10,325)^a

Characteristic	Total	Men	Women	p-value
N (%)	10,325	3,766 (36.5)	6,559 (63.5)	—
No. cases/ person-year	2,159 /53,678	854 /19,369	1,305 /34,308	
Age, y	56.9 ± 9.73	58.5 ± 9.73	55.9 ± 9.61	<.0001
Higher education ^b	31.6	38.3	27.7	<.0001
Regular exercise ^c	21.2	20.0	21.8	0.0277
Current smoker				
Never-smoker	70.9	27.3	95.9	<.0001
Past smoker	13.2	33.9	1.30	
Current smoker	16.0	38.8	2.85	
Menopausal status	70.1	—	70.1	—
Family history of hypertension	17.8	13.9	20.0	<.0001
Current drinker	42.1	62.6	30.3	<.0001
Alcohol consumption, ml/d	11.3 ± 35.9	26.8 ± 54.4	2.42 ± 10.9	<.0001
Body Mass index, kg/m ²	23.9 ± 3.00	23.7 ± 2.85	24.0 ± 3.08	<.0001
Waist circumference, cm	82.6 ± 8.66	84.5 ± 7.91	81.5 ± 8.88	<.0001
Total energy intake, kcal/d	1,579 ± 438	1,699 ± 445	1,509 ± 418	<.0001
Modified DASH scores ^d	17.4 ± 3.14	17.2 ± 3.18	17.5 ± 3.11	0.0004
Total flavonoids, mg/d	176 ± 164	161 ± 142	185 ± 175	—
Flavonols	18.1 ± 14.0	18.1 ± 13.5	18.0 ± 14.3	0.7977
Flavones	1.85 ± 1.28	1.73 ± 1.13	1.91 ± 1.36	<.0001
Flavanones	9.03 ± 10.9	7.11 ± 9.07	10.1 ± 11.7	<.0001
Flavan-3-ols	58.4 ± 112	55.7 ± 99.4	60.0 ± 118	0.0461
Anthocyanins	8.87 ± 10.8	7.25 ± 9.03	9.66 ± 11.7	<.0001
Isoflavones	19.1 ± 15.3	19.7 ± 15.8	18.7 ± 15.0	<.0001
Proanthocyanins	60.7 ± 62.3	51.1 ± 51.7	66.2 ± 67.0	<.0001

^a Values are expressed as mean ± standard deviation for continuous variables and percentages for categorical variables.

^b Higher education level (≥12 years of schooling).

^c Regular exercise (≥3 times/week and ≥30 min/session).

^d Modified Dietary Approaches to Stop Hypertension (DASH) scores were calculated based on six out of eight components after excluding fruits and vegetables and modifying the 'Nuts/legumes' into 'Nuts' without legumes.

Supplementary Table S2. Contribution of the seven flavonoid subclasses to flavonoid intake (n = 10,325)

Ranking ^a	Subclasses	Men			Women		
		Median (IQR), mg/day	Contribution, % ^b	Variation, % ^c	Median (IQR), mg/day	Contribution, %	Variation, %
1	Proanthocyanindins	36.5 (19.7-64.2)	33.06	22.3	46.4 (24.3-85.8)	37.34	24.21
2	Flavan-3-ols	17.4 (6.36-52.7)	24.07	74.2	18.5 (7.06-52.6)	22.34	73.17
3	Isoflavones	15.1 (8.58-25.9)	16.92	1.82	14.2 (8.31-25.0)	14.58	0.7
4	Flavonols	15.0 (9.83-22.3)	15.13	1.00	14.5 (8.99-22.6)	13.03	0.12
5	Flavanones	4.58 (1.82-9.21)	4.80	0.53	6.79 (2.95-13.3)	6.01	0.11
6	Anthocyanins	4.60 (1.90-9.01)	4.57	0.14	6.19 (2.63-12.7)	5.32	0.36
7	Flavones	1.49 (0.97-2.16)	1.45	0.00	1.60 (1.02-2.43)	1.38	1.34
Total	Flavonoids	118 (69.3-206)	100%	100%	133 (75.8-236)	100%	100%

IQR: Interquartile range.

^a Ranking of the contribution of individual subclasses to total flavonoid intake.

^b Contribution to total flavonoid intake.

^c Proportion of explained variation by the regression model.

Supplementary Table S3. Incidence rate ratio of hypertension by quartiles of dietary intake of flavonoids and their subclasses (n = 10,325)

Sensitivity analysis	Men (n = 3766)						Women (n = 6559)					
	Q1	Q2	Q3	Q4	<i>P</i> _{linearity} ^a	<i>P</i> _{non-linearity} ^b	Q1	Q2	Q3	Q4	<i>P</i> _{linearity}	<i>P</i> _{non-linearity}
Total flavonoids												
After censoring CVD and cancer	1 (ref)	0.66 (0.55-0.81)	0.71 (0.58-0.86)	0.84 (0.68-1.04)	0.9985	<0.0001	1 (ref)	0.74 (0.64-0.86)	0.81 (0.69-0.95)	0.89 (0.74-1.07)	0.8887	0.0002
Excluding cases within the first 2 year ^c	1 (ref)	0.69 (0.56-0.84)	0.67 (0.54-0.84)	0.82 (0.66-1.03)	0.7762	<0.0001	1 (ref)	0.79 (0.67-0.94)	0.83 (0.70-1.00)	0.82 (0.67-1.00)	0.2752	0.0350
Only non-users of antioxidant component supplement ^c	1 (ref)	0.67 (0.55-0.82)	0.67 (0.54-0.84)	0.81 (0.64-1.02)	0.6062	<0.0001	1 (ref)	0.67 (0.56-0.79)	0.82 (0.69-0.98)	0.85 (0.70-1.05)	0.8839	<0.0001
Flavonols												
After censoring CVD and cancer	1 (ref)	0.63 (0.52-0.76)	0.69 (0.57-0.84)	0.75 (0.61-0.93)	0.1510	<0.0001	1 (ref)	0.74 (0.63-0.86)	0.72 (0.61-0.84)	0.83 (0.69-0.98)	0.2808	<0.0001
Excluding cases within the first 2 year	1 (ref)	0.66 (0.54-0.81)	0.73 (0.60-0.90)	0.84 (0.68-1.05)	0.6960	0.0002	1 (ref)	0.74 (0.63-0.87)	0.69 (0.58-0.83)	0.76 (0.63-0.93)	0.0718	0.0003
Only non-users of antioxidant component supplement	1 (ref)	0.63 (0.52-0.78)	0.69 (0.56-0.85)	0.79 (0.63-0.99)	0.2915	<0.0001	1 (ref)	0.72 (0.61-0.85)	0.70 (0.59-0.84)	0.83 (0.68-1.01)	0.3114	<0.0001
Flavones												
After censoring CVD and cancer	1 (ref)	0.78 (0.64-0.94)	0.68 (0.55-0.83)	0.91 (0.73-1.13)	0.6824	0.0001	1 (ref)	0.93 (0.80-1.08)	0.79 (0.67-0.93)	0.96 (0.80-1.15)	0.6652	0.0074
Excluding cases within the first 2 year	1 (ref)	0.89 (0.73-1.09)	0.72 (0.58-0.90)	0.97 (0.77-1.24)	0.9303	0.0039	1 (ref)	0.91 (0.77-1.07)	0.76 (0.64-0.91)	0.86 (0.71-1.05)	0.1573	0.0320

Only non-users of antioxidant component supplement	1 (ref)	0.75 (0.62-0.92)	0.64 (0.51-0.80)	0.89 (0.70-1.12)	0.5147	<0.0001	1 (ref)	0.90 (0.76-1.06)	0.83 (0.70-1.00)	0.98 (0.80-1.20)	0.9252	0.0690
Flavanones												
After censoring CVD and cancer	1 (ref)	0.65 (0.54-0.79)	0.57 (0.47-0.69)	0.73 (0.60-0.89)	0.0955	<0.0001	1 (ref)	0.78 (0.67-0.90)	0.77 (0.66-0.89)	0.73 (0.62-0.86)	0.0033	0.0120
Excluding cases within the first 2 year	1 (ref)	0.68 (0.56-0.83)	0.58 (0.47-0.72)	0.75 (0.60-0.93)	0.1588	<0.0001	1 (ref)	0.82 (0.70-0.96)	0.80 (0.68-0.95)	0.72 (0.60-0.87)	0.0032	0.1700
Only non-users of antioxidant component supplement	1 (ref)	0.62 (0.51-0.75)	0.55 (0.45-0.68)	0.67 (0.54-0.83)	0.0201	<0.0001	1 (ref)	0.79 (0.67-0.93)	0.79 (0.66-0.93)	0.74 (0.61-0.90)	0.0129	0.0450
Flavan-3ols												
After censoring CVD and cancer	1 (ref)	0.64 (0.53-0.78)	0.69 (0.57-0.84)	0.77 (0.63-0.93)	0.8121	<0.0001	1 (ref)	0.82 (0.71-0.96)	0.89 (0.76-1.05)	0.86 (0.73-1.02)	0.5101	0.0450
Excluding cases within the first 2 year	1 (ref)	0.62 (0.50-0.76)	0.70 (0.57-0.86)	0.74 (0.60-0.91)	0.6609	<0.0001	1 (ref)	0.92 (0.78-1.08)	0.96 (0.81-1.15)	0.89 (0.74-1.07)	0.3214	0.5800
Only non-users of antioxidant component supplement	1 (ref)	0.65 (0.53-0.79)	0.67 (0.55-0.83)	0.71 (0.58-0.88)	0.2816	<0.0001	1 (ref)	0.79 (0.67-0.93)	0.90 (0.75-1.07)	0.86 (0.71-1.03)	0.5650	0.0210
Anthocyanins												
After censoring CVD and cancer	1 (ref)	0.73 (0.61-0.88)	0.62 (0.51-0.76)	0.72 (0.58-0.88)	0.0331	<0.0001	1 (ref)	0.76 (0.66-0.89)	0.72 (0.62-0.84)	0.74 (0.63-0.87)	0.0081	0.0008
Excluding cases within the first 2 year	1 (ref)	0.74 (0.61-0.89)	0.62 (0.50-0.76)	0.70 (0.56-0.87)	0.0222	0.0003	1 (ref)	0.79 (0.67-0.94)	0.78 (0.66-0.92)	0.71 (0.60-0.85)	0.0029	0.0530
Only non-users of antioxidant component supplement	1 (ref)	0.70 (0.58-0.85)	0.57 (0.46-0.70)	0.69 (0.55-0.86)	0.0196	<0.0001	1 (ref)	0.79 (0.66-0.93)	0.74 (0.62-0.88)	0.79 (0.66-0.94)	0.0597	0.0054
Isoflavones												
After censoring CVD and cancer	1 (ref)	0.76 (0.63-0.92)	0.62 (0.51-0.76)	0.76 (0.62-0.93)	0.0579	<0.0001	1 (ref)	0.76 (0.65-0.88)	0.68 (0.58-0.80)	0.81 (0.69-0.95)	0.1356	<0.0001
Excluding cases within the first 2 year	1 (ref)	0.79 (0.65-0.97)	0.67 (0.55-0.83)	0.83 (0.67-1.03)	0.3365	0.0013	1 (ref)	0.76 (0.65-0.91)	0.69 (0.58-0.83)	0.82 (0.68-0.98)	0.2417	0.00025
Only non-users of antioxidant component supplement	1 (ref)	0.74 (0.60-0.90)	0.59 (0.48-0.73)	0.74 (0.60-0.91)	0.0370	<0.0001	1 (ref)	0.73 (0.62-0.87)	0.67 (0.56-0.79)	0.77 (0.64-0.92)	0.0567	<0.0001
Proanthocyanidins												
After censoring CVD and cancer	1 (ref)	0.82 (0.68-0.98)	0.74 (0.61-0.90)	0.76 (0.61-0.94)	0.0487	0.0540	1 (ref)	0.79 (0.68-0.92)	0.71 (0.61-0.83)	0.73 (0.61-0.87)	0.0043	0.0029
Excluding cases within the first 2 year	1 (ref)	0.77 (0.63-0.94)	0.75 (0.61-0.92)	0.72 (0.57-0.91)	0.0345	0.0650	1 (ref)	0.81 (0.68-0.95)	0.74 (0.62-0.88)	0.68 (0.56-0.83)	0.0080	0.0710
Only non-users of antioxidant component supplement	1 (ref)	0.77 (0.63-0.93)	0.69 (0.56-0.86)	0.70 (0.56-0.88)	0.0135	0.0270	1 (ref)	0.77 (0.65-0.91)	0.70 (0.59-0.84)	0.78 (0.64-0.95)	0.0609	0.0013

DASH, Dietary Approaches to Stop Hypertension) score.

The multivariable model was adjusted for age (years), higher education level (≥ 12 years of schooling), regular exercise (≥ 3 times/week and ≥ 30 min/session), smoking (current/past/non-smokers for men and current/non-smokers for women), current drinkers (yes or no), body mass index (BMI), total energy intake (kcal/d), family history of hypertension (yes or no), menopausal status (yes or no for only women), and baseline blood pressures.

^a *P* values for linear trends were obtained by treating the median value of each group as a continuous variable.

^b *P* values for non-linear trends were obtained by Wald test to compare the deviance of the linear trend model to the deviance of the categorical model.

^c Among participants excluding cases within the first 2 years after baseline (n = 3,568 for men, n = 6,224 for women)

^d Among only non-users of antioxidant component supplements (n = 3,112 for men, n = 4,914 for women)

Supplementary Table S4. Incidence rate ratio of hypertension by quartiles of dietary intake of 35 individual flavonoid compounds (n = 10,325)


Flavonoids, mg/d	Men (n = 3766)						Women (n = 6559)					
	Q1	Q2	Q3	Q4	<i>P</i> _{linearity} ^a	<i>P</i> _{non-linearity} ^b	Q1	Q2	Q3	Q4	<i>P</i> _{linearity} ^a	<i>P</i> _{non-linearity} ^b
Flavonols												
Quercetin	1 (ref)	0.72 (0.60-0.87)	0.69 (0.57-0.84)	0.77 (0.62-0.95)	0.0851	0.0009	1 (ref)	0.72 (0.62-0.83)	0.72 (0.62-0.84)	0.85 (0.72-1.00)	0.4000	<0.0001
Kaempferol	1 (ref)	0.70 (0.58-0.84)	0.69 (0.57-0.83)	0.81 (0.67-0.98)	0.3972	0.0001	1 (ref)	0.86 (0.74-1.00)	0.78 (0.67-0.92)	0.86 (0.73-1.01)	0.2226	0.0180
Myricetin	1 (ref)	0.72 (0.59-0.87)	0.90 (0.75-1.09)	0.97 (0.80-1.18)	0.3774	0.0012	1 (ref)	0.82 (0.71-0.95)	0.77 (0.66-0.89)	0.92 (0.78-1.08)	0.8652	0.0006
Isorhamnetin	1 (ref)	0.67 (0.56-0.80)	0.66 (0.55-0.79)	0.75 (0.62-0.90)	0.0855	<0.0001	1 (ref)	0.73 (0.63-0.85)	0.68 (0.58-0.79)	0.68 (0.58-0.80)	0.0002	0.0002
Flavones												
Luteolin	1 (ref)	0.68 (0.57-0.82)	0.66 (0.54-0.79)	0.71 (0.58-0.87)	0.0127	0.0002	1 (ref)	0.78 (0.67-0.90)	0.72 (0.62-0.84)	0.89 (0.76-1.05)	0.5016	<0.0001
Apigenin	1 (ref)	0.80 (0.67-0.96)	0.72 (0.59-0.88)	0.99 (0.81-1.22)	0.4619	0.0003	1 (ref)	0.94 (0.81-1.09)	0.81 (0.69-0.94)	0.94 (0.79-1.12)	0.5063	0.0220
Flavanones												
Hesperetin	1 (ref)	0.59 (0.50-0.71)	0.60 (0.50-0.72)	0.70 (0.58-0.84)	0.1358	<0.0001	1 (ref)	0.76 (0.66-0.88)	0.78 (0.67-0.91)	0.77 (0.66-0.91)	0.0605	0.0017
Naringenin	1 (ref)	0.59 (0.49-0.71)	0.57 (0.47-0.68)	0.69 (0.57-0.83)	0.0306	<0.0001	1 (ref)	0.78 (0.67-0.90)	0.75 (0.64-0.87)	0.73 (0.62-0.85)	0.0016	0.0074
Eriodictyol	1 (ref)	0.71 (0.60-0.86)	0.72 (0.59-0.87)	0.80 (0.66-0.98)	0.7221	0.0002	1 (ref)	0.83 (0.71-0.96)	0.83 (0.71-0.97)	0.85 (0.72-1.01)	0.4341	0.0220
Flavan-3-ols												
Catechin	1 (ref)	0.79 (0.66-0.95)	0.71 (0.59-0.86)	0.86 (0.70-1.05)	0.6054	0.0015	1 (ref)	0.87 (0.75-1.01)	0.73 (0.62-0.86)	0.84 (0.70-0.99)	0.1145	0.0018
Epicatechin	1 (ref)	0.66 (0.55-0.80)	0.73 (0.61-0.88)	0.86 (0.71-1.05)	0.8501	<0.0001	1 (ref)	0.76 (0.66-0.88)	0.72 (0.61-0.84)	0.92 (0.77-1.08)	0.8057	<0.0001
Epigallocatechin	1 (ref)	0.74 (0.62-0.89)	0.71 (0.58-0.86)	0.76 (0.63-0.92)	0.3267	0.0006	1 (ref)	0.74 (0.64-0.86)	0.88 (0.76-1.03)	0.77 (0.65-0.90)	0.0753	0.0004
Epicatechin gallate (ECG)	1 (ref)	0.65 (0.54-0.78)	0.66 (0.55-0.80)	0.72 (0.60-0.86)	0.3707	<0.0001	1 (ref)	0.79 (0.68-0.91)	0.90 (0.77-1.05)	0.82 (0.70-0.96)	0.2143	0.0070
Epigallocatechin gallate (EGCG)	1 (ref)	0.64 (0.53-0.76)	0.61 (0.51-0.73)	0.67 (0.56-0.81)	0.2157	<0.0001	1 (ref)	0.77 (0.67-0.90)	0.85 (0.73-0.99)	0.76 (0.65-0.89)	0.0532	0.0030
Gallocatechin	1 (ref)	0.61 (0.51-0.73)	0.60 (0.50-0.72)	0.69 (0.57-0.82)	0.3949	<0.0001	1 (ref)	0.79 (0.68-0.91)	0.86 (0.75-1.00)	0.80 (0.68-0.94)	0.1552	0.0058
Theaflavin	1 (ref)	0.59 (0.48-0.73)	0.67 (0.56-0.79)	0.75 (0.63-0.89)	0.2261	<0.0001	1 (ref)	0.66 (0.55-0.79)	0.87 (0.76-1.00)	0.80 (0.69-0.92)	0.0667	<0.0001
Thearubigin	1 (ref)	0.59 (0.48-0.73)	0.67 (0.56-0.79)	0.75 (0.63-0.89)	0.2261	<0.0001	1 (ref)	0.66 (0.55-0.79)	0.87 (0.76-0.99)	0.80 (0.69-0.92)	0.0723	<0.0001
Theaflavin 3'-gallate	1 (ref)	0.59 (0.49-0.73)	0.67 (0.56-0.79)	0.75 (0.63-0.89)	0.2261	<0.0001	1 (ref)	0.66 (0.55-0.79)	0.87 (0.76-0.995)	0.80 (0.69-0.92)	0.6667	<0.0001
Theaflavin 3-3'-digallate	1 (ref)	0.59 (0.48-0.73)	0.67 (0.56-0.79)	0.75 (0.63-0.89)	0.2261	<0.0001	1 (ref)	0.66 (0.55-0.79)	0.87 (0.76-0.995)	0.80 (0.69-0.92)	0.6667	<0.0001
Anthocyanins												
Cyanidin	1 (ref)	0.80 (0.67-0.96)	0.65 (0.54-0.80)	0.72 (0.59-0.89)	0.0124	0.0023	1 (ref)	0.71 (0.61-0.83)	0.66 (0.57-0.77)	0.72 (0.60-0.85)	0.0102	<0.0001
Delphinidin	1 (ref)	0.65 (0.54-0.78)	0.60 (0.50-0.72)	0.69 (0.57-0.84)	0.0588	<0.0001	1 (ref)	0.78 (0.68-0.90)	0.67 (0.58-0.78)	0.68 (0.58-0.80)	<.0001	0.0002
Malvidin	1 (ref)	0.62 (0.52-0.74)	0.54 (0.45-0.65)	0.69 (0.57-0.84)	0.1408	<0.0001	1 (ref)	0.80 (0.69-0.92)	0.68 (0.59-0.80)	0.67 (0.57-0.78)	<.0001	0.0021
Pelargonidin	1 (ref)	0.76 (0.64-0.90)	0.56 (0.46-0.68)	0.74 (0.61-0.90)	0.0881	<0.0001	1 (ref)	0.80 (0.69-0.92)	0.77 (0.66-0.90)	0.66 (0.57-0.78)	<.0001	0.0230
Peonidin	1 (ref)	0.63 (0.53-0.75)	0.56 (0.47-0.68)	0.69 (0.57-0.83)	0.0764	<0.0001	1 (ref)	0.74 (0.64-0.85)	0.67 (0.57-0.78)	0.66 (0.57-0.77)	<.0001	0.0001
Petunidin	1 (ref)	0.64 (0.54-0.77)	0.58 (0.49-0.70)	0.68 (0.56-0.83)	0.0586	<0.0001	1 (ref)	0.76 (0.66-0.88)	0.69 (0.59-0.80)	0.66 (0.57-0.77)	<.0001	0.0005
Isoflavones												
Daidzein	1 (ref)	0.78 (0.65-0.94)	0.62 (0.51-0.74)	0.79 (0.65-0.96)	0.0910	<0.0001	1 (ref)	0.76 (0.65-0.89)	0.68 (0.58-0.79)	0.80 (0.68-0.93)	0.0913	<0.0001
Genistein	1 (ref)	0.73 (0.61-0.88)	0.61 (0.51-0.74)	0.76 (0.63-0.92)	0.0734	<0.0001	1 (ref)	0.78 (0.67-0.91)	0.68 (0.58-0.80)	0.80 (0.68-0.93)	0.0584	0.0001
Glycitein	1 (ref)	0.74 (0.62-0.89)	0.59 (0.49-0.71)	0.77 (0.64-0.94)	0.1096	<0.0001	1 (ref)	0.74 (0.63-0.86)	0.68 (0.58-0.80)	0.80 (0.68-0.93)	0.1315	<0.0001
Biochanin A	1 (ref)	0.73 (0.61-0.87)	0.60 (0.49-0.73)	0.74 (0.60-0.90)	0.0868	<0.0001	1 (ref)	0.77 (0.67-0.89)	0.68 (0.58-0.80)	0.72 (0.61-0.85)	0.0033	0.0002

Formononetin	1 (ref)	0.90 (0.74-1.09)	0.87 (0.72-1.05)	1.13 (0.93-1.38)	0.1652	0.0250	1 (ref)	0.74 (0.64-0.86)	0.92 (0.79-1.06)	0.87 (0.75-1.01)	0.3491	0.0006
Proanthocyanidins												
Dimer	1 (ref)	0.80 (0.67-0.96)	0.76 (0.62-0.91)	0.77 (0.62-0.95)	0.0572	0.0530	1 (ref)	0.89 (0.76-1.03)	0.74 (0.63-0.87)	0.83 (0.69-0.98)	0.0613	0.0062
Trimer	1 (ref)	0.86 (0.72-1.03)	0.86 (0.71-1.04)	0.85 (0.68-1.05)	0.1979	0.3900	1 (ref)	0.76 (0.65-0.88)	0.78 (0.67-0.91)	0.80 (0.67-0.96)	0.0704	0.0024
4-6mers	1 (ref)	0.87 (0.73-1.05)	0.76 (0.63-0.92)	0.77 (0.62-0.94)	0.0268	0.1500	1 (ref)	0.78 (0.67-0.90)	0.68 (0.58-0.79)	0.72 (0.61-0.86)	0.0049	0.0002
7-10mers	1 (ref)	0.76 (0.64-0.91)	0.59 (0.48-0.71)	0.69 (0.57-0.85)	0.0121	<0.0001	1 (ref)	0.76 (0.65-0.88)	0.71 (0.61-0.82)	0.69 (0.58-0.82)	0.0012	0.0006
Polymer	1 (ref)	0.69 (0.58-0.83)	0.67 (0.55-0.80)	0.67 (0.55-0.83)	0.0093	0.0003	1 (ref)	0.79 (0.68-0.91)	0.72 (0.62-0.84)	0.72 (0.61-0.85)	0.0016	0.0049


Multivariable model was adjusted for age (years), higher education level (≥ 12 schooling years), regular exercise (≥ 3 times/week and ≥ 30 min/session), smoking (current/past/non-smokers for men and current/non-smokers for women), current drinkers (yes or no), body mass index (BMI), total energy intake (kcal/d), family history of hypertension (yes or no), menopausal status (yes or no for only women), and baseline blood pressures.

^a P values for linear trends were obtained by treating the median value of each group as a continuous variable.

^b P values for non-linear trends were obtained by comparing the deviance difference between linear trend model on 1 degree of freedom (d.f.) and ℓ ordered categorical model on $\ell - 1$ d.f.



Supplementary Figure S1. Timeline of study follow-up in KoGES_CAVAS cohort



Supplementary Figure S2. Flowchart of study in KoGES_CAVAS cohort